{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:25:31Z","timestamp":1775024731040,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ijcard.2020.12.074","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T14:38:27Z","timestamp":1609425507000},"page":"205-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Filling the gap between Guidelines and Real World in the cardiovascular approach to the diabetic patients: the need for a call to action"],"prefix":"10.1016","volume":"329","author":[{"given":"Francesco","family":"Maranta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Cianfanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Cianflone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2020.12.074_bb0005","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/eurheartj\/ehz966","volume":"41","author":"European Heart Journal","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0010","first-page":"3035","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"34","author":"Cosentino","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0020","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0025","series-title":"Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2. Diabetes from Res. to Clin. Pract","first-page":"129","author":"Maranta","year":"2020"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0030","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12933-020-01022-7","article-title":"Report from the 5th cardiovascular outcome trial (CVOT) summit","volume":"19","author":"Schnell","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0035","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0040","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes","volume":"358","author":"G\u00e6de","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2016-000294","article-title":"Large-scale survey of rates of achieving targets for blood glucose, blood pressure, and lipids and prevalence of complications in type 2 diabetes (JDDM 40)","volume":"4","author":"Yokoyama","year":"2016","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0050","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2337\/dc19-2165","article-title":"Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease-A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V","volume":"43","author":"Ferrannini","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0055","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1001\/jamainternmed.2019.2396","article-title":"Evaluation of the Cascade of Diabetes Care in the United States, 2005-2016","volume":"179","author":"Kazemian","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0060","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/dom.13625","article-title":"Composite cardiovascular risk factor target achievement and its predictors in US adults with diabetes: The Diabetes Collaborative Registry","volume":"21","author":"Fan","year":"2019","journal-title":"Diabetes, Obes Metab"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0065","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0070","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijcard.2020.03.025","article-title":"Novel glucose lowering agents are associated with a lower risk of cardiovascular and adverse events in type 2 diabetes: A population based analysis","volume":"310","author":"Elharram","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0075","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00125-019-05039-w","article-title":"2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"63","author":"Buse","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0080","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc21-S009","article-title":"Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes\u20142021","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0085","article-title":"Guideline recommendations and the positioning of newer drugs in type 2 diabetes care","author":"Marx","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0090","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-020-01154-w","article-title":"Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes","volume":"19","author":"Schernthaner","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0095","article-title":"Adoption of the ADA\/EASD guidelines in 10 Eastern and Southern European countries: physician survey and good clinical practice recommendations from an International Expert Panel","author":"Cardio-Metabolic Academy Europe East","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108151","article-title":"COVID-19 and diabetes management: What should be considered?","volume":"163","author":"Ceriello","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0105","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.2337\/dci20-0002","article-title":"Is Coronary Artery Disease Inevitable in Type 2 Diabetes? From a Glucocentric to a Holistic View on Patient Management","volume":"43","author":"Ferrannini","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0115","article-title":"EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study","author":"Ray","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0120","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ahj.2008.03.005","article-title":"Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004","volume":"156","author":"Ghandehari","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0125","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2337\/diacare.28.5.1029","article-title":"The challenge of achieving national cholesterol goals in patients with diabetes","volume":"28","author":"Kennedy","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0130","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijcard.2018.04.068","article-title":"Non-achievement of LDL-cholesterol targets in patients with diabetes at very-high cardiovascular risk receiving statin treatment: Incidence and risk factors","volume":"268","author":"Breuker","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0135","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S2213-8587(16)00003-6","article-title":"Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data","volume":"4","author":"Sattar","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0140","series-title":"National Report on Medicines use in Italy. Year 2019","author":"The Medicines Utilisation Monitoring Centre (OSMED)","year":"2020"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0145","series-title":"Idelson-Gnocchi 1908 srl","article-title":"AMD Annals 2020. Diabetes Mellitus type 2","author":"Manicardi","year":"2021"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0150","first-page":"80","article-title":"Cardiologist and Diabetologist crosstalk in the era of cardiovascular outcome trials of novel glucose-lowering drugs","volume":"21","author":"Maranta","year":"2018","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10.1016\/j.ijcard.2020.12.074_bb0155","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ijcard.2018.08.090","article-title":"Improving health literacy in patients with chronic conditions: A call to action","volume":"273","author":"Dunn","year":"2018","journal-title":"Int J Cardiol"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527320343229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527320343229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:51:39Z","timestamp":1759092699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527320343229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":31,"alternative-id":["S0167527320343229"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2020.12.074","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Filling the gap between Guidelines and Real World in the cardiovascular approach to the diabetic patients: the need for a call to action","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2020.12.074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}